# Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

> **NCT04530318** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Judit Pich** · enrollment: 45 (estimated)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **OTHER:** Autologous peripheral blood differentiated adult tolerogenic dendritic cells expanded
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04530318
- **Lead sponsor:** Judit Pich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-27
- **Primary completion:** 2025-09-09
- **Final completion:** 2026-03-15
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530318, "Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04530318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*